No biomarker

News alerts, weekly reports and conference planners

No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed RTD Sensitive: A1 - Approval cisplatin + pemetrexed RTD Sensitive : A1	cisplatin + pemetrexed RTD Sensitive: A1 - Approval cisplatin + pemetrexed RTD Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1

No biomarker

Associations